Skip to main content
Erschienen in: Journal of Bone and Mineral Metabolism 3/2015

01.05.2015 | Case Report

Atypical femoral fracture in a patient treated with denosumab

verfasst von: Kareeann Sok Fun Khow, Tuck Yean Yong

Erschienen in: Journal of Bone and Mineral Metabolism | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Atypical fractures of the femur (AFF) have been reported in the literature at an increasing rate over the past decade, especially in patients who have been on prolonged courses of bisphosphonates. However, there have only been a few reported cases of AFF in those treated with other antiresorptive medications. In this case report, a 72-year-old woman with chronic obstructive pulmonary disease and osteoporosis presented with an atraumatic right femoral fracture in the setting of denosumab use. In contrast with other reports, this patient had received bisphosphonate therapy for a short duration before the switch to denosumab. While causality between the fracture and denosumab use cannot be established in this case, there is a growing number of reports of a similar association. Ongoing vigilance is required to determine whether denosumab is associated with or potentially a cause of AFF.
Literatur
1.
Zurück zum Zitat Giannini S, Chiarello E, Tedesco G, Cadossi M, Luciani D, Mazzotti A, Donati DM (2013) Atypical femoral fractures. Clin Cases Miner Bone Metab 10:30–33PubMedCentralPubMed Giannini S, Chiarello E, Tedesco G, Cadossi M, Luciani D, Mazzotti A, Donati DM (2013) Atypical femoral fractures. Clin Cases Miner Bone Metab 10:30–33PubMedCentralPubMed
2.
Zurück zum Zitat Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD et al (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1–23CrossRefPubMed Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD et al (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1–23CrossRefPubMed
3.
4.
Zurück zum Zitat Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwinski E et al (2013) The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab 98:4483–4492CrossRefPubMedCentralPubMed Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwinski E et al (2013) The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab 98:4483–4492CrossRefPubMedCentralPubMed
5.
Zurück zum Zitat Paparodis R, Buehring B, Pelley EM, Binkley N (2013) A case of an unusual subtrochanteric fracture in a patient receiving denosumab. Endocr Pract 19:e64–e68CrossRefPubMed Paparodis R, Buehring B, Pelley EM, Binkley N (2013) A case of an unusual subtrochanteric fracture in a patient receiving denosumab. Endocr Pract 19:e64–e68CrossRefPubMed
6.
Zurück zum Zitat Thompson RN, Armstrong CL, Heyburn G (2013) Bilateral atypical femoral fractures in a patient prescribed denosumab--A case report. Bone 61C:44–47 Thompson RN, Armstrong CL, Heyburn G (2013) Bilateral atypical femoral fractures in a patient prescribed denosumab--A case report. Bone 61C:44–47
7.
Zurück zum Zitat Villiers J, Clark DW, Jeswani T, Webster S, Hepburn AL (2013) An atraumatic femoral fracture in a patient with rheumatoid arthritis and osteoporosis treated with denosumab. Case Rep Rheumatol 2013:249872PubMedCentralPubMed Villiers J, Clark DW, Jeswani T, Webster S, Hepburn AL (2013) An atraumatic femoral fracture in a patient with rheumatoid arthritis and osteoporosis treated with denosumab. Case Rep Rheumatol 2013:249872PubMedCentralPubMed
8.
Zurück zum Zitat Drampalos E, Skarpas G, Barbounakis N, Michos I (2014) Atypical femoral fractures bilaterally in a patient receiving denosumab. Acta Orthop 85:3–5CrossRefPubMedCentralPubMed Drampalos E, Skarpas G, Barbounakis N, Michos I (2014) Atypical femoral fractures bilaterally in a patient receiving denosumab. Acta Orthop 85:3–5CrossRefPubMedCentralPubMed
10.
Zurück zum Zitat Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765CrossRefPubMed Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765CrossRefPubMed
14.
Zurück zum Zitat Li J, Miller MA, Hutchins GD, Burr DB (2005) Imaging bone microdamage in vivo with positron emission tomography. Bone 37:819–824CrossRefPubMed Li J, Miller MA, Hutchins GD, Burr DB (2005) Imaging bone microdamage in vivo with positron emission tomography. Bone 37:819–824CrossRefPubMed
15.
Zurück zum Zitat Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302:1055–1061CrossRefPubMed Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302:1055–1061CrossRefPubMed
16.
Zurück zum Zitat Ettinger B, Burr DB, Ritchie RO (2013) Proposed pathogenesis for atypical femoral fractures: lessons from materials research. Bone 55:495–500CrossRefPubMed Ettinger B, Burr DB, Ritchie RO (2013) Proposed pathogenesis for atypical femoral fractures: lessons from materials research. Bone 55:495–500CrossRefPubMed
17.
Zurück zum Zitat Chiang CY, Zebaze RM, Ghasem-Zadeh A, Iuliano-Burns S, Hardidge A, Seeman E (2013) Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone 52:360–365CrossRefPubMed Chiang CY, Zebaze RM, Ghasem-Zadeh A, Iuliano-Burns S, Hardidge A, Seeman E (2013) Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone 52:360–365CrossRefPubMed
Metadaten
Titel
Atypical femoral fracture in a patient treated with denosumab
verfasst von
Kareeann Sok Fun Khow
Tuck Yean Yong
Publikationsdatum
01.05.2015
Verlag
Springer Japan
Erschienen in
Journal of Bone and Mineral Metabolism / Ausgabe 3/2015
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-014-0606-6

Weitere Artikel der Ausgabe 3/2015

Journal of Bone and Mineral Metabolism 3/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.